GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GRAIL Inc (MEX:GRAL) » Definitions » NonCurrent Deferred Liabilities

GRAIL (MEX:GRAL) NonCurrent Deferred Liabilities : MXN6,244 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is GRAIL NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

GRAIL's non-current deferred liabilities for the quarter that ended in Mar. 2025 was MXN6,244 Mil.

GRAIL NonCurrent Deferred Liabilities Historical Data

The historical data trend for GRAIL's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRAIL NonCurrent Deferred Liabilities Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
135.66 - 1,385.68 558.81 7,213.15

GRAIL Quarterly Data
Dec18 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,649.46 7,734.07 7,386.27 7,213.15 6,243.68

GRAIL NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of GRAIL's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


GRAIL Business Description

Traded in Other Exchanges
Address
1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.